These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 17268732)
1. Morphological aspects as prognostic factors in malignant mesothelioma: a study of 58 cases. Motta AB; Pinheiro G; Antonângelo L; Parra ER; Monteiro MM; Pereira JC; Takagaki T; Terra Filho M; Martins S; Capelozzi VL J Bras Pneumol; 2006; 32(4):322-32. PubMed ID: 17268732 [TBL] [Abstract][Full Text] [Related]
2. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Comin CE; Novelli L; Boddi V; Paglierani M; Dini S Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372 [TBL] [Abstract][Full Text] [Related]
3. In search of a positive immunohistochemical marker for mesothelioma: an update. Ordóñez NG Adv Anat Pathol; 1998 Jan; 5(1):53-60. PubMed ID: 9868512 [No Abstract] [Full Text] [Related]
4. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma. Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584 [TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K Pathol Int; 2007 Apr; 57(4):190-9. PubMed ID: 17316414 [TBL] [Abstract][Full Text] [Related]
6. [Pseudomesotheliomatous adenocarcinoma of the lung. Immunohistochemical study with special reference to detection of blood group isoantigens and Ber-EP4 antigen]. Moch H; Kiener S; Dalquen P; Gudat F Pathologe; 1993 Jan; 14(1):11-5. PubMed ID: 8095719 [No Abstract] [Full Text] [Related]
7. Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan. Nojiri S; Gemba K; Aoe K; Kato K; Yamaguchi T; Sato T; Kubota K; Kishimoto T Jpn J Clin Oncol; 2011 Jan; 41(1):32-9. PubMed ID: 20798232 [TBL] [Abstract][Full Text] [Related]
8. Lymphohistiocytoid mesothelioma. An often misdiagnosed variant of sarcomatoid malignant mesothelioma. Khalidi HS; Medeiros LJ; Battifora H Am J Clin Pathol; 2000 May; 113(5):649-54. PubMed ID: 10800396 [TBL] [Abstract][Full Text] [Related]
9. The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion. Dejmek A; Hjerpe A Diagn Cytopathol; 2005 Mar; 32(3):160-6. PubMed ID: 15690331 [TBL] [Abstract][Full Text] [Related]
10. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Edwards JG; Swinson DE; Jones JL; Waller DA; O'Byrne KJ Lung Cancer; 2006 Dec; 54(3):399-407. PubMed ID: 17049671 [TBL] [Abstract][Full Text] [Related]
11. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Cury PM; Butcher DN; Fisher C; Corrin B; Nicholson AG Mod Pathol; 2000 Feb; 13(2):107-12. PubMed ID: 10697265 [TBL] [Abstract][Full Text] [Related]
12. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos. Gube M; Taeger D; Weber DG; Pesch B; Brand P; Johnen G; Müller-Lux A; Gross IM; Wiethege T; Weber A; Raithel HJ; Kraus T; Brüning T Arch Toxicol; 2011 Mar; 85(3):185-92. PubMed ID: 20737138 [TBL] [Abstract][Full Text] [Related]
13. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Kao SC; Pavlakis N; Harvie R; Vardy JL; Boyer MJ; van Zandwijk N; Clarke SJ Clin Cancer Res; 2010 Dec; 16(23):5805-13. PubMed ID: 20956618 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic significance of carcinoembryonic antigen in the differential diagnosis of malignant mesothelioma. Mezger J; Lamerz R; Permanetter W J Thorac Cardiovasc Surg; 1990 Dec; 100(6):860-6. PubMed ID: 2147220 [TBL] [Abstract][Full Text] [Related]
15. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma. Ylagan LR; Zhai J Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333 [TBL] [Abstract][Full Text] [Related]
16. [Immunohistochemistry in the differential diagnosis of mesothelioma and adenocarcinoma. Evaluation of 5 new antibodies and 6 traditional antibodies]. Chenard-Neu MP; Kabou A; Mechine A; Brolly F; Orion B; Bellocq JP Ann Pathol; 1998 Dec; 18(6):460-5. PubMed ID: 10051912 [TBL] [Abstract][Full Text] [Related]
17. Prognostic values of stromal proportion and PCNA, Ki-67, and p53 proteins in patients with resected adenocarcinoma of the lung. Demarchi LM; Reis MM; Palomino SA; Farhat C; Takagaki TY; Beyruti R; Saldiva PH; Capelozzi VL Mod Pathol; 2000 May; 13(5):511-20. PubMed ID: 10824922 [TBL] [Abstract][Full Text] [Related]
19. [Immunohistochemistry of mesotheliomas. Technique and current diagnostic contribution of immunohistochemical markers. General review]. Galateau-Salle F Arch Anat Cytol Pathol; 1993; 41(5-6):212-22. PubMed ID: 8135582 [TBL] [Abstract][Full Text] [Related]
20. [Diagnostic value of tissue polypeptide antigen in pleural effusions with malignant pleural mesothelioma]. Tokuyama T; Yoneda T; Hamada K; Yoshikawa M; Fu A; Tomoda K; Nakaya M; Narita N; Tamura M; Kitamura K Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Jan; 33(1):39-43. PubMed ID: 7699966 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]